Most Read Articles
Christina Lau, 4 days ago
Progress in the treatment of rare cancers is named Advance of the Year by the American Society of Clinical Oncology (ASCO).
Jackey Suen, 08 Jul 2016

Scientists have refined anti-CD19 chimeric antigen receptor (CAR) T cell therapy, an investigational treatment for advanced non-Hodgkin’s lymphoma, with initial results showing significantly higher response and survival rates than the standard repertoire.

Pretreatment PNI, NLR predict survival in early stage hepatocellular carcinoma

02 Dec 2018

Pretreatment prognostic nutritional index (PNI) and neutrophil-to-lymphocyte ratio (NLR) predict survival in patients with early stage hepatocellular carcinoma (HCC) undergoing radiofrequency ablation (RFA), reports a recent study.

The study included 118 newly-diagnosed HCC patients (mean age 69.4±10.4 years; 63 percent male) undergoing RFA. Over a median follow-up of 36 months, 14 percent (n=17) died due to HCC progression, 10 percent (n=12) due to liver failure and 13 percent (n=15) due to reasons unrelated to liver failure.

The resulting overall survival (OS) rates at years 1, 3 and 5 after RFA were 90 percent, 67 percent and 52 percent, respectively.

Survival analyses showed that inflammation-based indices strongly predicted OS. For instance, participants with high NLR had shorter median OS durations than those with low NLR (cutoff, 2.5; 33 vs 38.1 months). In contrast, those with high vs low PNI had longer median OS (cutoff, 40; 38.2 vs 33.2 months).

Moreover, those with combined low NLR and high PNI had the most favourable outcomes (median OS, 38.6 months). Platelet-to-lymphocyte ratio was not a prognostic factor for survival in HCC patients after RFA.

These were confirmed in multivariate Cox proportional hazards analysis, which showed that high NLR (hazard ratio [HR], 1.94; 95 percent CI, 1.05–3.59; p=0.034) and low PNI (HR, 0.38; 0.20–0.72; p=0.003) were significant and independent factors for OS.

Other such factors were a history of end-stage renal disease (HR, 3.60; 1.48–8.76; p=0.005) and elevated α-foetoprotein levels (200 ng/mL; HR, 4.61; 1.75–12.13; p=0.002).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Christina Lau, 4 days ago
Progress in the treatment of rare cancers is named Advance of the Year by the American Society of Clinical Oncology (ASCO).
Jackey Suen, 08 Jul 2016

Scientists have refined anti-CD19 chimeric antigen receptor (CAR) T cell therapy, an investigational treatment for advanced non-Hodgkin’s lymphoma, with initial results showing significantly higher response and survival rates than the standard repertoire.